Method of treatment
CA 2445913 A1 · Owner: Zhang, Zhongxin · Inventors: Brenner, Barry M.; Shahinfar, Shahnaz; Zhang, Zhongxin
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This disclosure relates to a method of preventing end stage renal disease using an angiotensin II antagonist in patients with impaired renal function. Angiotensin II antagonists such as candesartan cilexetil eprosartan, irbesartan, losartan, tasosartan telmisartan, valsartan, 2-butyl-4-chloro-1- (2'-tetrazol-5-yl)biphenyl-4-yl)methylimidazolecarboxylic acid and 3-(2'- (tetrazol-5-yl)-1,1'-biphen-4-yl)methyl-5,7-dimethyl-2-ethyl-3H-imidazo4,5bpyridine, or pharmaceutically acceptable salts thereof are useful.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 10, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 10, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 10, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.